Search
Now showing items 1-5 of 5
Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
(SPRINGER JAPAN KK, 2023-07-01)
BACKGROUND: The efficacy and safety of olaparib compared with placebo in the subset of patients from Japan in the phase 3 OlympiA trial (NCT02032823) are reported here and contextualized with reference to the global OlympiA ...
Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes.
(FRONTIERS MEDIA SA, 2023-06-22)
BACKGROUND: Intracellular communication within the tumour is complex and extracellular vesicles (EVs) have been identified as major contributing factors for the cell-to-cell communication in the local and distant tumour ...
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
(AMER ASSOC CANCER RESEARCH, 2023-09-15)
PURPOSE: The TNT trial (NCT00532727) showed no evidence of carboplatin superiority over docetaxel in metastatic triple-negative breast cancer (mTNBC), but carboplatin benefit was observed in the germline BRCA1/2 mutation ...
Systemic Therapy for Hereditary Breast Cancers.
(W B SAUNDERS CO-ELSEVIER INC, 2023-02-01)
Approximately 5% to 10% of all breast cancers are hereditary; many of which are caused by pathogenic variants in genes required for homologous recombination, including BRCA1 and BRCA2. Here we discuss systemic treatment ...
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
(Elsevier BV, 2023-12-08)